Optic nerve disease and the WFS1 gene
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at people who have a change in the WFS1 gene to understand if it can cause a certain type of vision loss (optic atrophy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you have a change in the WFS1 gene (found by genetic testing).
- You do not have a change in the WFS2 gene.
- You are willing to have your medical history and genetic information reviewed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds an international online registry to learn how Wolfram syndrome (and related WFS1 conditions) changes over time. It may help researchers understand the disease course and improve future care by collecting health and family history data.
This study follows people with a genetic form of optic atrophy over time to understand how vision changes. It does not test a treatment but helps doctors learn more about the condition to improve care.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This study uses a special eye scan (OCT) to look at the layer of nerve fibers in the retina of people who carry (or don't carry) a specific gene change linked to Leber Hereditary Optic Neuropathy (NOHL). The goal is to find early warning signs in the blood that might show who is at risk of losing vision.
This trial tests a single gene therapy injection under the retina for boys with X-linked retinoschisis, a condition that causes vision loss. It aims to see if the treatment is safe and can improve vision.
Hear when a new Wolfram Syndrome 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.